Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Current Deferred Revenue (2022 - 2025)

Jin Medical International's Current Deferred Revenue history spans 4 years, with the latest figure at $495357.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 26.22% year-over-year to $495357.0; the TTM value through Sep 2025 reached $495357.0, down 26.22%, while the annual FY2025 figure was $495357.0, 26.22% down from the prior year.
  • Current Deferred Revenue for Q3 2025 was $495357.0 at Jin Medical International, down from $671414.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $830305.0 in Q3 2022 and bottomed at $495357.0 in Q3 2025.
  • The 4-year median for Current Deferred Revenue is $690756.5 (2023), against an average of $676793.8.
  • The largest annual shift saw Current Deferred Revenue decreased 5.45% in 2024 before it dropped 26.22% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $830305.0 in 2022, then fell by 14.48% to $710099.0 in 2023, then fell by 5.45% to $671414.0 in 2024, then dropped by 26.22% to $495357.0 in 2025.
  • Per Business Quant, the three most recent readings for ZJYL's Current Deferred Revenue are $495357.0 (Q3 2025), $671414.0 (Q3 2024), and $710099.0 (Q3 2023).